Skip to content

    Publications

    Review select publications related to our three translational research projects and the Biospecimen and Pathology Core. 

    Project 1: Developing a Diagnostic Test and Therapeutic Agents for Fibrolamellar Hepatocellular Carcinoma

    2024

    Increased protein kinase A activity induces fibrolamellar hepatocellular carcinoma features independent of DNAJB1 

    Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma

    GalNAc-conjugated siRNA targeting the DNAJB1-PRKACA fusion junction in fibrolamellar hepatocellular carcinoma

    Targeted degradation of protein kinase A via a stapled peptide PROTAC

    2023

    Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma

    Oncogenic addiction of Fibrolamellar hepatocellular carcinoma to the fusion kinase DNAJB1-PRKACA

    Alternative lengthening of telomeres in primary hepatic neoplasms

    Unique morphologic findings in the liver after stereotactic radiation for cholangiocarcinoma

    2022

    Clinical and demographic predictors of survival for fibrolamellar carcinoma patients-A patient community, registry-based study

    Clinical Outcomes in Fibrolamellar Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors

    Targeting BCL-XL in fibrolamellar hepatocellular carcinoma

    Human liver organoids for disease modeling of fibrolamellar carcinoma

    Project 2: Therapeutic Inhibition of Fibroblast Growth Factor and YAP Signaling in Cholangiocarcinoma

    2024

    YAP-TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escape

    Metabolome-wide association identifies altered metabolites and metabolic pathways in the serum of patients with cholangiocarcinoma

    Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma

    2023

    LCK inhibtion downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinoma

    2022

    Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy

    Project 3: Development of a New Viral Immunotherapeutic Approach for Hepatocellular Carcinoma

    2025

    T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy

    2023

    Trap and ambush therapy using sequential primary and tumor escape-selective oncolytic viruses

    Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers

    2022

    Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

    PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-β receptor I versus II

    Biostatistics and Bioinformatics Core

    2022

    Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: Implications for tumor molecular classification

    Biospecimen and Pathology Core

    2024

    Genome-wide DNA methylation markers associated with metabolic liver cancer

    Combined antitumor effect of the serine protease urokinase inhibitor upamostat and the sphingosine kinase 2 inhibitor opaganib on cholangiocarcinoma patient-derived xenografts

    Genome-wide association study identifies high-impact susceptibility loci for HCC in North America

    2023

    CS-iCCA, a new clinically based staging system for intrahepatic cholangiocarcinoma: Establishment and external validation

    Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma

    Multitrait genome-wide analyses identify new susceptibility loci and candidate drugs to primary sclerosing cholangitis

    Premature aging and reduced cancer incidence associated with near-complete body-wide Myc inactivation

    2022

    Aspirin, statins, non-aspirin NSAIDs, metformin, and the risk of biliary cancer: A Swedish population-based cohort study

    Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes

    Hepatic adenomas in patients 60 and older are enriched for HNF1A inactivation and malignant transformation

    Two distinct stem cell-like subtypes of hepatocellular carcinoma with clinical significance and their therapeutic potentials

    Developmental Research Program and Career Enhancement Program

    2025

    CLO25-087: Low serum pseudocholinesterase level predicts HCC mortality as accurately as the ALBI or MESIAH score

    Role of long chain Acyl-CoA synthetases in MASH-driven hepatocellular carcinoma and ferroptosis

    Utility of methylated DNA markers for the diagnosis of malignant biliary strictures

    2024

    PTEN deficiency induces an extrahepatic cholangitis-cholangiocarcinoma continuum via aurora kinase A in mice

    2023

    Cholangiocarcinoma — novel biological insights and therapeutic strategies

    Immunobiology of cholangiocarcinoma

    Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes

    Metabolic reprogramming and its clinical implication for liver cancer

    2022

    Emerging immunotherapy for HCC: A guide for hepatologists

    3X your impact!

    Give Now!

    Your gift can go 3X as far to shape the future of cancer care.

    Give Now!